Follow
Davide Melisi
Davide Melisi
Associate professor, University of Verona
Verified email at univr.it
Title
Cited by
Cited by
Year
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
GK Abou-Alfa, V Sahai, A Hollebecque, G Vaccaro, D Melisi, R Al-Rajabi, ...
The Lancet Oncology 21 (5), 671-684, 2020
11372020
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
D Melisi, S Ishiyama, GM Sclabas, JB Fleming, Q Xia, G Tortora, ...
Molecular cancer therapeutics 7 (4), 829-840, 2008
3632008
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
D Melisi, R Garcia-Carbonero, T Macarulla, D Pezet, G Deplanque, ...
British journal of cancer 119 (10), 1208-1214, 2018
2252018
Key cancer cell signal transduction pathways as therapeutic targets
R Bianco, D Melisi, F Ciardiello, G Tortora
European journal of cancer 42 (3), 290-294, 2006
2132006
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
M Simbolo, M Fassan, A Ruzzenente, A Mafficini, LD Wood, V Corbo, ...
Oncotarget 5 (9), 2839, 2014
2082014
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative …
G Tortora, R Caputo, V Damiano, D Melisi, R Bianco, G Fontanini, ...
Clinical Cancer Research 9 (4), 1566-1572, 2003
1972003
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1
D Melisi, Q Xia, G Paradiso, J Ling, T Moccia, C Carbone, A Budillon, ...
Journal of the National Cancer Institute 103 (15), 1190-1204, 2011
1792011
Vascular endothelial growth factor receptor-1 contributes to resistance to anti–epidermal growth factor receptor drugs in human cancer cells
R Bianco, R Rosa, V Damiano, G Daniele, T Gelardi, S Garofalo, V Tarallo, ...
Clinical Cancer Research 14 (16), 5069-5080, 2008
1772008
Angiopoietin-like proteins in angiogenesis, inflammation and cancer
C Carbone, G Piro, V Merz, F Simionato, R Santoro, C Zecchetto, ...
International journal of molecular sciences 19 (2), 431, 2018
1752018
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
IM Silverman, A Hollebecque, L Friboulet, S Owens, RC Newton, H Zhen, ...
Cancer discovery 11 (2), 326-339, 2021
1722021
EMT and treatment resistance in pancreatic cancer
N Gaianigo, D Melisi, C Carbone
Cancers 9 (9), 122, 2017
1442017
NF-κB as a target for pancreatic cancer therapy
C Carbone, D Melisi
Expert opinion on therapeutic targets 16 (sup2), S1-S10, 2012
1232012
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
TS Bekaii-Saab, JW Valle, E Van Cutsem, L Rimassa, J Furuse, T Ioka, ...
Future Oncology 16 (30), 2385-2399, 2020
1212020
NF-κB as a target for cancer therapy
D Melisi, PJ Chiao
Expert opinion on therapeutic targets 11 (2), 133-144, 2007
1182007
HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research
F Pietrantonio, M Caporale, F Morano, M Scartozzi, A Gloghini, F De Vita, ...
International journal of cancer 139 (12), 2859-2864, 2016
1142016
IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-κB activation
Z Zhuang, HQ Ju, M Aguilar, T Gocho, H Li, T Iida, H Lee, X Fan, H Zhou, ...
Clinical Cancer Research 22 (6), 1432-1444, 2016
1112016
Secreted interleukin-1α induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-κB
D Melisi, J Niu, Z Chang, Q Xia, B Peng, S Ishiyama, DB Evans, PJ Chiao
Molecular Cancer Research 7 (5), 624-633, 2009
1112009
Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma
L Maggino, G Malleo, G Marchegiani, E Viviani, C Nessi, D Ciprani, ...
JAMA surgery 154 (10), 932-942, 2019
1082019
Angiogenesis: a target for cancer therapy
G Tortora, D Melisi, F Ciardiello
Current pharmaceutical design 10 (1), 11-26, 2004
1062004
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
D Melisi, DY Oh, A Hollebecque, E Calvo, A Varghese, E Borazanci, ...
Journal for immunotherapy of cancer 9 (3), 2021
1052021
The system can't perform the operation now. Try again later.
Articles 1–20